Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2023-11-19 Director's Dealing
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - Prof Fiona Wood 2 pages 219.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a change in securities held by a director, including the nature of the interest, number of securities before and after the change, and the nature of the change (issue of options). This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is not an announcement of a report, nor a full financial report, but a specific regulatory filing about insider transactions.
2023-11-19 English
Application for quotation of securities - OCC 8 pages 30.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities by Orthocell Limited, detailing the number and type of securities to be quoted on the ASX, issue dates, and related information. It references a previous Appendix 3B announcement about the securities issuance. The content focuses on the issuance and quotation of shares following shareholder approval at an AGM. This type of document is a formal announcement related to capital changes, specifically the listing or quotation of new shares on the exchange. It is not a financial report, earnings release, or management discussion. Therefore, the appropriate classification is a Share Issue/Capital Change announcement (SHA). The document length and detail confirm it is not a brief report publication announcement or a regulatory filing fallback.
2023-11-14 English
Cleansing Notice 1 page 128.0KB
Share Issue/Capital Change Classification · 100% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of shares following shareholder approval at the Annual General Meeting. It details the issuance of 250,000 fully paid ordinary shares at a specified price and confirms compliance with relevant sections of the Corporations Act. The document is short (3146 characters) and primarily serves as a formal announcement of a share issue rather than a detailed financial report or analysis. It does not contain financial statements or substantive financial data but rather a regulatory notice about capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2023-11-14 English
Change of Director's Interest Notice-John Van Der Wielen 2 pages 220.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the change, and related contract interests. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is 3831 characters, which is consistent with a detailed insider trading notice rather than a full financial report or announcement.
2023-11-14 English
Successful OrthoATI clinical trial 6 pages 403.2KB
Regulatory Filings Classification · 85% confidence The document is a detailed announcement of clinical trial results for a medical treatment called OrthoATI™. It includes comprehensive study design, patient characteristics, primary and secondary outcomes, statistical significance, and future strategic plans. The content is scientific and clinical in nature, focusing on the efficacy and benefits of the treatment compared to surgery. There is no indication that this is a financial report, earnings release, regulatory filing, or any other corporate governance or capital market document. It is not a transcript, proxy, or voting result announcement. The document is a clinical study result announcement, which does not fit into the typical financial or corporate filing categories provided. Given the absence of any financial data, regulatory references, or corporate governance content, the best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2023-11-13 English
Notification regarding unquoted securities - OCC 9 pages 33.9KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification about the issue of unquoted equity securities by Orthocell Limited. It includes specifics such as the number of securities issued, the exercise price, expiry dates, and references to ASX listing rules. The content focuses on the issuance of new securities under an employee incentive scheme and provides detailed breakdowns of securities on issue. There is no indication of financial performance data, management discussion, or regulatory certifications. The document is not an announcement of a report but a direct notification of a capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length (8015 characters) supports it being a full notification rather than a brief announcement or certification.
2023-11-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.